Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1977 2
1980 1
1984 2
1991 1
1993 1
2001 1
2005 2
2008 1
2012 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
Vale CL, Tierney J, Bull SJ, Symonds PR. Vale CL, et al. Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD003915. doi: 10.1002/14651858.CD003915.pub4. Cochrane Database Syst Rev. 2012. PMID: 22895938 Free PMC article. Review.
OBJECTIVES: To assess any benefits or adverse effects of cytotoxic chemotherapy in women with advanced, recurrent or metastatic endometrial adenocarcinoma. SEARCH METHODS: Systematic searches of MEDLINE, EMBASE, CENTRAL and the Cochrane Gynaecological Cancer …
OBJECTIVES: To assess any benefits or adverse effects of cytotoxic chemotherapy in women with advanced, recurrent or metastatic en …
Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
Humber C, Tierney J, Symonds P, Collingwood M, Kirwan J, Williams C, Green J. Humber C, et al. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003915. doi: 10.1002/14651858.CD003915.pub3. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2012 Aug 15;(8):CD003915. doi: 10.1002/14651858.CD003915.pub4. PMID: 16235346 Updated. Review.
OBJECTIVES: To assess any benefits or adverse effects of cytotoxic chemotherapy in women with advanced, recurrent or metastatic endometrial adenocarcinoma. SEARCH STRATEGY: The major medical literature databases were searched for all known randomised c …
OBJECTIVES: To assess any benefits or adverse effects of cytotoxic chemotherapy in women with advanced, recurrent or metastatic en …
Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
Humber C, Tierney J, Symonds P, Collingwood M, Kirwan J, Williams C, Green J. Humber C, et al. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003915. doi: 10.1002/14651858.CD003915.pub2. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003915. doi: 10.1002/14651858.CD003915.pub3. PMID: 16034916 Updated. Review.
OBJECTIVES: To assess any benefits or adverse effects of cytotoxic chemotherapy in women with advanced, recurrent or metastatic endometrial adenocarcinoma. SEARCH STRATEGY: The major medical literature databases were searched for all known randomised c …
OBJECTIVES: To assess any benefits or adverse effects of cytotoxic chemotherapy in women with advanced, recurrent or metastatic en …
Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen.
Gebbia V, Testa A, Borsellino N, Ferrera P, Tirrito M, Palmeri S. Gebbia V, et al. Ann Oncol. 2001 Jun;12(6):767-72. doi: 10.1023/a:1011160110205. Ann Oncol. 2001. PMID: 11484950 Free article. Clinical Trial.
Six patients had stable disease and nine progressed. All patients who achieved a clinical complete response had only a single site of disease at entry, but no association was noted between number of involved sites and likehood of achieving PR. ...CONCLUSIONS: The CDDP + VN …
Six patients had stable disease and nine progressed. All patients who achieved a clinical complete response had only a single site of …
Adriamycin and cis-diamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma.
Seltzer V, Vogl SE, Kaplan BH. Seltzer V, et al. Gynecol Oncol. 1984 Nov;19(3):308-13. doi: 10.1016/0090-8258(84)90197-5. Gynecol Oncol. 1984. PMID: 6542050
Adriamycin (50 mg/m2) and cis-diamminedichloroplatinum (50 mg/m2) were administered every 21 days to treat metastatic endometrial adenocarcinoma. This regimen resulted in three responses (one complete and two partial) in nine women (33%). ...
Adriamycin (50 mg/m2) and cis-diamminedichloroplatinum (50 mg/m2) were administered every 21 days to treat metastatic endometrial …
The endometrial adenocarcinoma as a model for hormone-dependency and hormone-responsiveness of gynaecological cancers.
Bonte J. Bonte J. Eur J Obstet Gynecol Reprod Biol. 1984 Dec;18(5-6):335-41. doi: 10.1016/0028-2243(84)90055-8. Eur J Obstet Gynecol Reprod Biol. 1984. PMID: 6526120
The evident direct and the possible indirect mechanisms of action of medroxyprogesterone and tamoxifen on the endometrial adenocarcinoma are elucidated in vitro as well as in vivo with special regard to histological, histochemical, cytological, biochemical, endocrinological and …
The evident direct and the possible indirect mechanisms of action of medroxyprogesterone and tamoxifen on the endometrial adenocarcinoma are …
Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma.
Piver MS, Barlow JJ, Lurain JR, Blumenson LE. Piver MS, et al. Cancer. 1980 Jan 15;45(2):268-72. doi: 10.1002/1097-0142(19800115)45:2<268::aid-cncr2820450211>3.0.co;2-8. Cancer. 1980. PMID: 6985833 Clinical Trial.
A prospective trial was initiated in 1972 utilizing Depo-Provera in women with metastatic or recurrent endometrial adenocarcinoma to evaluate if the objective response and survival would be significantly improved in comparison to patients previously treated with Delalutin …
A prospective trial was initiated in 1972 utilizing Depo-Provera in women with metastatic or recurrent endometrial adenocarcinoma to …
Doxorubicin-cyclophosphamide: effective chemotherapy for advanced endometrial adenocarcinoma.
Muggia FM, Chia G, Reed LJ, Romney SL. Muggia FM, et al. Am J Obstet Gynecol. 1977 Jun 1;128(3):314-9. doi: 10.1016/0002-9378(77)90629-9. Am J Obstet Gynecol. 1977. PMID: 860739
Eight of 11 consecutive patients with metastatic endometrial adenocarcinoma completed more than one course of treatment with a doxorubicin-cyclophosphamide combination. ...Moreover, if the degree of efficacy reported herein is confirmed, it will justify cl …
Eight of 11 consecutive patients with metastatic endometrial adenocarcinoma completed more than one course of treatment …
13 results